POM
Pomdoctor·NASDAQ
--
--(--)
--
--(--)
POM fundamentals
During H1 2025, Pomdoctor (POM) reported revenue of 24.36M, a YoY change of 17.87%. Net income was -2.78M, a YoY change of -43.82%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2019 | FY,2020 | FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | TTM |
|---|
Start Date | Jan 1, 2019 | Jan 1, 2020 | Jan 1, 2021 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2024 | Jan 1, 2024 | Jan 1, 2025 | -- |
End Date | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Jun 30, 2022 | Dec 31, 2022 | Jun 30, 2023 | Dec 31, 2023 | Jun 30, 2024 | Dec 31, 2024 | Jun 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 26.65M -- | 21.64M -18.80% | 33.80M +56.18% | 16.36M -- | 35.55M +5.19% | 17.63M +7.75% | 42.94M +20.77% | 20.66M +17.21% | 46.93M +9.30% | 24.36M +17.87% | 50.62M -- |
Sales and Services Revenue | 26.65M -- | 21.64M -18.80% | 33.80M +56.18% | 16.36M -- | 35.55M +5.19% | -- -- | 42.94M +20.77% | 20.66M -- | 46.93M +9.30% | 24.36M +17.87% | 50.62M -- |
Cost of Revenue | 15.61M -- | 13.41M -14.10% | 25.56M +90.64% | 12.53M -- | 27.60M +7.98% | 14.93M +19.18% | 37.48M +35.82% | 17.31M +15.96% | 40.40M +7.77% | 20.40M +17.84% | 43.48M -- |
Cost of Goods and Services | -- -- | -- -- | -- -- | -- -- | 27.60M -- | -- -- | 37.48M +35.82% | 17.31M -- | 40.40M +7.77% | 20.40M +17.84% | 43.48M -- |
Gross Profit | 11.04M -- | 8.23M -25.44% | 8.24M +0.07% | 3.83M -- | 7.95M -3.46% | -- -- | 5.45M -31.43% | 3.35M -- | 6.53M +19.81% | 3.95M +18.02% | 7.14M -- |
Operating Expenses | 20.28M -- | 45.08M +122.31% | 20.74M -53.99% | 4.65M -- | 8.48M -59.14% | -- -- | 8.59M +1.32% | 4.57M -- | 10.07M +17.23% | 5.83M +27.48% | 11.32M -- |
Selling, General and Administrative Expenses | 19.59M -- | 44.78M +128.61% | 16.16M -63.92% | 4.36M -- | 7.96M -50.76% | -- -- | 7.89M -0.86% | 4.36M -- | 9.35M +18.55% | 5.34M +22.35% | 10.32M -- |
Selling and Marketing Expenses | -- -- | -- -- | -- -- | -- -- | 6.88M -- | -- -- | 6.15M -10.59% | 3.42M -- | 7.72M +25.52% | 3.88M +13.17% | 8.17M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | -- -- | 1.07M -- | -- -- | 1.73M +61.46% | 940.65K -- | 1.63M -6.17% | 1.46M +55.74% | 2.15M -- |
Research and Development Expenses | 691.21K -- | 304.22K -55.99% | 671.93K +120.87% | 291.29K -- | 520.20K -22.58% | -- -- | 474.79K -8.73% | 207.49K -- | 411.28K -13.38% | 206.59K -0.43% | 410.38K -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 226.35K -- | 2.46K -- | 306.68K +35.49% | 284.95K +11494.07% | 589.17K -- |
Other Operating Expenses | -- -- | -- -- | 3.91M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | -9.23M -- | -36.85M -299.03% | -12.50M +66.07% | -819.79K -- | -521.12K +95.83% | -- -- | -3.13M -501.34% | -1.23M -- | -3.53M -12.75% | -1.88M -53.32% | -4.19M -- |
Non-Operating Income (Loss) | -1.33M -- | -2.46M -85.20% | -2.59M -5.26% | -1.36M -- | -2.35M +9.15% | -- -- | -2.07M +12.05% | -704.64K -- | -1.59M +23.42% | -896.96K -27.29% | -1.78M -- |
Other Non-Operating Income (Loss) | 41.51K -- | -317.12K -864.05% | -35.07K +88.94% | -55.09K -- | -31.08K +11.36% | -- -- | -119.92K -285.80% | 145.65K -- | 190.49K +258.85% | 6.38K -95.62% | 51.23K -- |
Net Interest Expense | 1.37M -- | 2.14M +56.46% | 2.56M +19.18% | 1.30M -- | 2.32M -9.12% | -- -- | 1.95M -16.04% | 850.28K -- | 1.78M -8.94% | 903.34K +6.24% | 1.83M -- |
Interest Expense | 1.37M -- | 2.14M +56.46% | 2.56M +19.18% | 1.30M -- | 2.32M -9.12% | -- -- | 1.95M -16.04% | 850.28K -- | 1.78M -8.94% | 903.34K +6.24% | 1.83M -- |
Pretax Income From Continuing Operations | -10.56M -- | -39.31M -272.12% | -15.09M +61.60% | -2.18M -- | -2.88M +80.95% | -2.99M -37.55% | -5.20M -80.99% | -1.93M +35.53% | -5.12M +1.64% | -2.78M -43.82% | -5.96M -- |
Income Tax Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- |
Net Income | -10.56M -- | -39.31M -272.12% | -15.09M +61.60% | -2.18M -- | -2.88M +80.95% | -2.99M -37.55% | -5.20M -80.99% | -1.93M +35.53% | -5.12M +1.64% | -2.78M -43.82% | -5.96M -- |
Net Income Attributable to Minority Interests | -21.52K -- | -6.41K +70.22% | -2.40K +62.61% | -220.81 -- | -272.43 +88.63% | -- -- | 148.88 +154.65% | 3.80K -- | 3.55K +2281.29% | -134.01 -103.52% | -391.99 -- |
Net Income Attributable to Owners of the Company | -10.54M -- | -39.30M -272.82% | -15.09M +61.60% | -2.18M -- | -2.88M +80.95% | -- -- | -5.20M -81.02% | -1.93M -- | -5.12M +1.57% | -2.78M -43.53% | -5.96M -- |
Other Adjustments | -- -- | -- -- | 14.47M -- | 7.82M -- | 15.32M +5.86% | -- -- | 15.27M -0.32% | 7.25M -- | 14.52M -4.95% | 7.32M +0.89% | 14.58M -- |
Net Income Attributable to Common Stockholders | -10.54M -- | -39.30M -272.82% | -29.56M +24.77% | -10.00M -- | -18.20M +38.45% | -- -- | -20.48M -12.53% | -9.19M -- | -19.64M +4.09% | -10.09M -9.87% | -20.55M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -546.29 -- | -716.64 -- | 991.96 +281.58% | 821.61 -- |
Total Comprehensive Income | -10.56M -- | -39.31M -272.12% | -15.09M +61.60% | -2.18M -- | -2.88M +80.95% | -2.99M -37.55% | -5.20M -80.99% | -1.93M +35.51% | -5.12M +1.62% | -2.77M -43.73% | -5.96M -- |
Total Comprehensive Income Attributable to Minority Interests | -- -- | -- -- | -2.40K -- | -220.81 -- | 15.32M +639484.84% | -- -- | 15.27M -0.31% | 3.80K -- | 14.52M -4.93% | -134.01 -103.52% | 14.52M -- |
Total Comprehensive Income Attributable to Owners of the Company | -10.56M -- | -39.31M -272.12% | -15.09M +61.61% | -2.18M -- | -18.20M -20.59% | -- -- | -20.48M -12.53% | -9.19M -- | -19.64M +4.09% | -10.09M -9.85% | -20.55M -- |
Basic EPS | -0.62 -- | -2.3 -270.97% | -7.31 -217.83% | -2.47 -- | -4.5 +38.44% | -2.53 -2.43% | -3.25 +27.78% | -1.46 +42.29% | -3.11 +4.31% | -1.6 -9.59% | -3.25 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -4.5 -- | -- -- | -3.25 +27.78% | -1.46 -- | -3.11 +4.31% | -1.6 -9.59% | -3.25 -- |
Diluted EPS | -0.62 -- | -2.3 -270.97% | -7.31 -217.83% | -2.47 -- | -4.5 +38.44% | -2.53 -2.43% | -3.25 +27.78% | -1.46 +42.29% | -3.11 +4.31% | -1.6 -9.59% | -3.25 -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -4.5 -- | -- -- | -3.25 +27.78% | -1.46 -- | -3.11 +4.31% | -1.6 -9.59% | -3.25 -- |
You can ask Aime
What were the key takeaways from Pomdoctor’s earnings call?What is Pomdoctor's latest dividend and current dividend yield?What is the market's earnings forecast for Pomdoctor next quarter?What does Pomdoctor do and what are its main business segments?What factors drove the changes in Pomdoctor's revenue and profit?What guidance did Pomdoctor's management provide for the next earnings period?What were the key takeaways from Pomdoctor's earnings call?Did Pomdoctor beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
